Accéder au contenu
Merck

Typhoid fever in Fiji: a reversible plague?

Tropical medicine & international health : TM & IH (2014-07-30)
Corinne N Thompson, Mike Kama, Shrish Acharya, Una Bera, John Clemens, John A Crump, Aggie Dawainavesi, Gordon Dougan, W John Edmunds, Kimberley Fox, Kylie Jenkins, M Imran Khan, Josefa Koroivueta, Myron M Levine, Laura B Martin, Eric Nilles, Virginia E Pitzer, Shalini Singh, Ratu Vereniki Raiwalu, Stephen Baker, Kim Mulholland
RÉSUMÉ

The country of Fiji, with a population of approximately 870 000 people, faces a growing burden of several communicable diseases including the bacterial infection typhoid fever. Surveillance data suggest that typhoid has become increasingly common in rural areas of Fiji and is more frequent amongst young adults. Transmission of the organisms that cause typhoid is facilitated by faecal contamination of food or water and may be influenced by local behavioural practices in Fiji. The Fijian Ministry of Health, with support from Australian Aid, hosted a meeting in August 2012 to develop comprehensive control and prevention strategies for typhoid fever in Fiji. International and local specialists were invited to share relevant data and discuss typhoid control options. The resultant recommendations focused on generating a clearer sense of the epidemiology of typhoid in Fiji and exploring the contribution of potential transmission pathways. Additionally, the panel suggested steps such as ensuring that recommended ciprofloxacin doses are appropriate to reduce the potential for relapse and reinfection in clinical cases, encouraging proper hand hygiene of food and drink handlers, working with water and sanitation agencies to review current sanitation practices and considering a vaccination policy targeting epidemiologically relevant populations.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
USP
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard